within Pharmacolibrary.Drugs.ATC.M;

model M09AX04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.1833333333333337e-06,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0158,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00697,
    k12             = 0.0158,
    k21             = 0.0158
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M09AX04</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Drisapersen is an antisense oligonucleotide designed to induce exon 51 skipping in the dystrophin gene and thereby restore dystrophin production in patients with Duchenne muscular dystrophy (DMD) amenable to this therapy. The drug was previously under development for the treatment of DMD but has not been approved for use due to lack of demonstrated efficacy and safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adolescent and adult male patients with Duchenne muscular dystrophy after subcutaneous dosing.</p><h4>References</h4><ol><li><p>Flanigan, KM, Voit, T, Rosales, XQ, Servais, L, Kraus, JE, Wardell, C, Morgan, A, Dorricott, S, Nakielny, J, Quarcoo, N, Liefaard, L, Drury, T, Campion, G, &amp; Wright, P (2014). Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. <i>Neuromuscular disorders : NMD</i> 24(1) 16–24. DOI:<a href=\"https://doi.org/10.1016/j.nmd.2013.09.004\">10.1016/j.nmd.2013.09.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24321374/\">https://pubmed.ncbi.nlm.nih.gov/24321374</a></p></li><li><p>Goemans, NM, Tulinius, M, van den Hauwe, M, Kroksmark, AK, Buyse, G, Wilson, RJ, van Deutekom, JC, de Kimpe, SJ, Lourbakos, A, &amp; Campion, G (2016). Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. <i>PloS one</i> 11(9) e0161955–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0161955\">10.1371/journal.pone.0161955</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27588424/\">https://pubmed.ncbi.nlm.nih.gov/27588424</a></p></li><li><p>McDonald, CM, Wong, B, Flanigan, KM, Wilson, R, de Kimpe, S, Lourbakos, A, Lin, Z, &amp; Campion, G (2018). Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. <i>Annals of clinical and translational neurology</i> 5(8) 913–926. DOI:<a href=\"https://doi.org/10.1002/acn3.579\">10.1002/acn3.579</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30128316/\">https://pubmed.ncbi.nlm.nih.gov/30128316</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M09AX04;
